home / stock / kdmn / kdmn news


KDMN News and Press, Kadmon Holdings Inc. From 08/13/19

Stock Information

Company Name: Kadmon Holdings Inc.
Stock Symbol: KDMN
Market: NASDAQ
Website: kadmon.com

Menu

KDMN KDMN Quote KDMN Short KDMN News KDMN Articles KDMN Message Board
Get KDMN Alerts

News, Short Squeeze, Breakout and More Instantly...

KDMN - Kadmon Fully Enrolls Pivotal Trial of KD025 for Chronic Graft-Versus-Host Disease

Company Remains on Track to Report Interim Analysis by End of 2019 NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that KD025-213, an open-label registration trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD)...

KDMN - Kadmon EPS beats by $0.24, misses on revenue

Kadmon (NYSE: KDMN ): Q2 GAAP EPS of $0.07 beats by $0.24 . More news on: Kadmon Holdings, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

KDMN - Kadmon Provides Business Update and Reports Second Quarter 2019 Financial Results

NEW YORK, NY / ACCESSWIRE / August 5, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the second quarter of 2019. “We have made steady progress advancing KD025 for the treatment of cGVHD and expect the s...

KDMN - Kadmon Holdings: Updates To Thesis, Systemic Sclerosis Study Gets Underway

Shares of Kadmon Holdings ( KDMN ) have lost a third of their value since I initially suggested readers purchase a pilot position after a solid performance at ASH in 2017. The stock is in the red by 15% since my March update piece reminded readers that lead program KD025 in cGVHD has a hig...

KDMN - Mid-stage study underway for Kadmon's KD025 in systemic sclerosis

The first patient has been dosed in a Phase 2 clinical trial evaluating Kadmon Holdings' (NYSE: KDMN ) lead candidate KD025 in patients with diffuse cutaneous systemic sclerosis (SSc), an inherited immune disorder characterized by fibrosis (scarring) of the skin and internal organs. ...

KDMN - Kadmon Doses First Patient in Phase 2 Clinical Trial of KD025 in Systemic Sclerosis

NEW YORK, NY / ACCESSWIRE / July 9, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company’s ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a chronic imm...

KDMN - MU, PLUG among premarket gainers

Aerohive Networks (NYSE: HIVE ) +39%  on being acquired by Extreme Networks. More news on: Aerohive Networks, Inc., Acasti Pharma Inc., Marathon Patent Group, Inc., Stocks on the move, Read more ...

KDMN - Leerink upgrades AbbVie in premarket analyst action

Baxter International (NYSE: BAX ) initiated with Sector Weight rating at KeyBanc. More news on: Baxter International Inc., Kadmon Holdings, Inc., Matinas BioPharma Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

KDMN - Kadmon Holdings (KDMN) Investor Presentation - Slideshow

The following slide deck was published by Kadmon Holdings, Inc. in conjunction with this Read more ...

KDMN - Kadmon to Present at the Jefferies 2019 Global Healthcare Conference

NEW YORK, NY / ACCESSWIRE / May 29, 2019 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference in New York on Wednesday, June 5, 2019 at 11:30 a.m. ET. A live a...

Previous 10 Next 10